- Reuters•2 months ago
Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin. As cancer drug prices spiral, the arrival of the first biosimilars or copies of biotech drugs, ones made inside living cells, puts European oncologists in the forefront of a treatment shift that could slash costs and expand patient access.
- Barrons.com•3 months ago
Wells Fargo Securities According to our legal consultant, court filings last week made clear that Janssen has significantly less leverage over Celltrion than previously understood in the ‘083 cell media litigation. The important new information is that Celltrion [of South Korea] has already successfully started purchasing the disputed cell media from General Electric (GE) HyClone’s Singapore location, instead of GE HyClone’s Utah location. Celltrion and [Johnson & Johnson (JNJ) unit] Janssen will still litigate several issues in February, including a fight over whether Celltrion owes cash damages for its alleged historic infringement.
- Business Wire•5 months ago
New statement from European Crohn's and Colitis Organisation supports switching to biosimilar from reference product in inflammatory bowel disease
Celltrion Healthcare welcomes the publication of the latest position paper from the European Crohn’s and Colitis Organisation on the use of biosimilars for inflammatory bowe
068270.KQ : Summary for Celltrion - Yahoo Finance
Celltrion, Inc. (068270.KQ)
KOSDAQ - KOSDAQ Delayed Price. Currency in KRW
Add to watchlist
|Day's Range||89,100.00 - 90,100.00|
|52 Week Range||83,904.80 - 113,333.00|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|